{"title":"68Ga-FAPi PET/CT对阴性或不明确18F-FDG PET/CT患者消化系统肿瘤分期或再分期的影响","authors":"Nalan Alan Selçuk, Gamze Beydağı, Kaan Akçay, Emre Demirci, Ayşegül Görmez, Bala Başak Öven, Serkan Çelik, Fatma Şen, Özge Kapar, Levent Kabasakal","doi":"10.4274/mirt.galenos.2024.50470","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to evaluate the potential efficacy of <sup>68</sup>Ga-fibroblast activation protein inhibitor (FAPi) positron emission tomography/computed tomography (PET/CT) for detecting, staging, and restaging digestive system malignancies that are <sup>18</sup>F-fluorodeoxyglucose (<sup>18</sup>F-FDG) negative or show equivocal <sup>18</sup>F-FDG uptake.</p><p><strong>Methods: </strong>We conducted a prospective analysis of 30 patients with pathologically confirmed primary tumors or metastases of the digestive system. Participants underwent <sup>68</sup>Ga-FAPi PET/CT and <sup>18</sup>F-FDG PET/CT imaging for staging or restaging purposes within the same week. The efficacy of <sup>68</sup>Ga-FAPi PET/CT was assessed by comparing its ability to detect lesions and influence disease staging with that of <sup>18</sup>F-FDG PET/CT.</p><p><strong>Results: </strong><sup>68</sup>Ga-FAPi PET/CT imaging was performed in 30 patients with <sup>18</sup>F-FDG-negative or indeterminate lesions. Of the 30 patients, 23 had gastric cancer and 7 had colorectal cancer. Among all patients, histopathological diagnosis of signet ring cell carcinoma was present in 15 (50%) patients. Primary tumor or local recurrence was detected in 19 (63%) patients, lymph node metastasis in 8 (27%) patients, visceral metastasis in 4 (13%) patients, peritoneal metastasis in 14 (47%) patients, and bone metastasis in 3 (10%) patients on <sup>68</sup>Ga-FAPi PET/CT images. All patients underwent histopathological confirmation on <sup>68</sup>Ga-FAPi PET/CT images. The disease stage was upgraded in 20 patients (67%) after <sup>68</sup>Ga-FAPi PET/CT imaging. Of the 20 patients, 12 had no evidence of recurrence or metastasis on <sup>18</sup>F-FDG PET/CT.</p><p><strong>Conclusion: </strong>Based on our study, <sup>68</sup>Ga-FAPi PET/CT alters the disease stage in the majority of gastrointestinal malignancies with negative or equivocal <sup>18</sup>F-FDG PET/CT findings. <sup>68</sup>Ga-FAPi PET/CT appears to be effective in both staging and restaging of gastrointestinal malignancies, such as signet-ring cell carcinomas of the stomach that frequently show low <sup>18</sup>F-FDG -avidity.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":"34 1","pages":"31-37"},"PeriodicalIF":0.9000,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11827526/pdf/","citationCount":"0","resultStr":"{\"title\":\"Impact of <sup>68</sup>Ga-FAPi PET/CT on Staging or Restaging Digestive System Tumors in Patients with Negative or Equivocal <sup>18</sup>F-FDG PET/CT Findings.\",\"authors\":\"Nalan Alan Selçuk, Gamze Beydağı, Kaan Akçay, Emre Demirci, Ayşegül Görmez, Bala Başak Öven, Serkan Çelik, Fatma Şen, Özge Kapar, Levent Kabasakal\",\"doi\":\"10.4274/mirt.galenos.2024.50470\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>This study aimed to evaluate the potential efficacy of <sup>68</sup>Ga-fibroblast activation protein inhibitor (FAPi) positron emission tomography/computed tomography (PET/CT) for detecting, staging, and restaging digestive system malignancies that are <sup>18</sup>F-fluorodeoxyglucose (<sup>18</sup>F-FDG) negative or show equivocal <sup>18</sup>F-FDG uptake.</p><p><strong>Methods: </strong>We conducted a prospective analysis of 30 patients with pathologically confirmed primary tumors or metastases of the digestive system. Participants underwent <sup>68</sup>Ga-FAPi PET/CT and <sup>18</sup>F-FDG PET/CT imaging for staging or restaging purposes within the same week. The efficacy of <sup>68</sup>Ga-FAPi PET/CT was assessed by comparing its ability to detect lesions and influence disease staging with that of <sup>18</sup>F-FDG PET/CT.</p><p><strong>Results: </strong><sup>68</sup>Ga-FAPi PET/CT imaging was performed in 30 patients with <sup>18</sup>F-FDG-negative or indeterminate lesions. Of the 30 patients, 23 had gastric cancer and 7 had colorectal cancer. Among all patients, histopathological diagnosis of signet ring cell carcinoma was present in 15 (50%) patients. Primary tumor or local recurrence was detected in 19 (63%) patients, lymph node metastasis in 8 (27%) patients, visceral metastasis in 4 (13%) patients, peritoneal metastasis in 14 (47%) patients, and bone metastasis in 3 (10%) patients on <sup>68</sup>Ga-FAPi PET/CT images. All patients underwent histopathological confirmation on <sup>68</sup>Ga-FAPi PET/CT images. The disease stage was upgraded in 20 patients (67%) after <sup>68</sup>Ga-FAPi PET/CT imaging. Of the 20 patients, 12 had no evidence of recurrence or metastasis on <sup>18</sup>F-FDG PET/CT.</p><p><strong>Conclusion: </strong>Based on our study, <sup>68</sup>Ga-FAPi PET/CT alters the disease stage in the majority of gastrointestinal malignancies with negative or equivocal <sup>18</sup>F-FDG PET/CT findings. <sup>68</sup>Ga-FAPi PET/CT appears to be effective in both staging and restaging of gastrointestinal malignancies, such as signet-ring cell carcinomas of the stomach that frequently show low <sup>18</sup>F-FDG -avidity.</p>\",\"PeriodicalId\":44681,\"journal\":{\"name\":\"Molecular Imaging and Radionuclide Therapy\",\"volume\":\"34 1\",\"pages\":\"31-37\"},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2025-02-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11827526/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Molecular Imaging and Radionuclide Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4274/mirt.galenos.2024.50470\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Imaging and Radionuclide Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4274/mirt.galenos.2024.50470","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
Impact of 68Ga-FAPi PET/CT on Staging or Restaging Digestive System Tumors in Patients with Negative or Equivocal 18F-FDG PET/CT Findings.
Objectives: This study aimed to evaluate the potential efficacy of 68Ga-fibroblast activation protein inhibitor (FAPi) positron emission tomography/computed tomography (PET/CT) for detecting, staging, and restaging digestive system malignancies that are 18F-fluorodeoxyglucose (18F-FDG) negative or show equivocal 18F-FDG uptake.
Methods: We conducted a prospective analysis of 30 patients with pathologically confirmed primary tumors or metastases of the digestive system. Participants underwent 68Ga-FAPi PET/CT and 18F-FDG PET/CT imaging for staging or restaging purposes within the same week. The efficacy of 68Ga-FAPi PET/CT was assessed by comparing its ability to detect lesions and influence disease staging with that of 18F-FDG PET/CT.
Results: 68Ga-FAPi PET/CT imaging was performed in 30 patients with 18F-FDG-negative or indeterminate lesions. Of the 30 patients, 23 had gastric cancer and 7 had colorectal cancer. Among all patients, histopathological diagnosis of signet ring cell carcinoma was present in 15 (50%) patients. Primary tumor or local recurrence was detected in 19 (63%) patients, lymph node metastasis in 8 (27%) patients, visceral metastasis in 4 (13%) patients, peritoneal metastasis in 14 (47%) patients, and bone metastasis in 3 (10%) patients on 68Ga-FAPi PET/CT images. All patients underwent histopathological confirmation on 68Ga-FAPi PET/CT images. The disease stage was upgraded in 20 patients (67%) after 68Ga-FAPi PET/CT imaging. Of the 20 patients, 12 had no evidence of recurrence or metastasis on 18F-FDG PET/CT.
Conclusion: Based on our study, 68Ga-FAPi PET/CT alters the disease stage in the majority of gastrointestinal malignancies with negative or equivocal 18F-FDG PET/CT findings. 68Ga-FAPi PET/CT appears to be effective in both staging and restaging of gastrointestinal malignancies, such as signet-ring cell carcinomas of the stomach that frequently show low 18F-FDG -avidity.
期刊介绍：
Molecular Imaging and Radionuclide Therapy (Mol Imaging Radionucl Ther, MIRT) is publishes original research articles, invited reviews, editorials, short communications, letters, consensus statements, guidelines and case reports with a literature review on the topic, in the field of molecular imaging, multimodality imaging, nuclear medicine, radionuclide therapy, radiopharmacy, medical physics, dosimetry and radiobiology.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
